TWST - Twist Bioscience Corporation
NEXT EARNINGS:
May 4, 2026
EPS Est: $-0.54
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$48.25
DETAILS
HIGH:
$52.00
LOW:
$41.00
MEDIAN:
$50.00
CONSENSUS:
$48.25
DOWNSIDE:
0.60%
Market Cap:
2.98B
Volume:
894,926
Avg Volume:
1,379,085
52 Week Range:
23.3-57.88
Sector:
Healthcare
Industry:
Medical - Diagnostics & Research
Beta:
2.27
Last Dividend:
$N/A
Exchange:
NASDAQ
Country:
US
Employees:
923
IPO Date:
2018-10-31
EPS (TTM):
-1.30
P/E Ratio:
-21.67
Revenue (TTM):
376.57M
Total Assets:
641.86M
Total Debt:
137.32M
Cash & Equiv:
183.05M
Rev Growth (5Y):
33.1%
EPS Growth (5Y):
N/A
FCF Growth (5Y):
N/A
ROCE:
-14.0%
Debt/Equity:
0.29
Earnings History
| Date | EPS Actual | EPS Est | EPS Surprise | Rev Actual | Rev Est | Rev Surprise |
|---|---|---|---|---|---|---|
| 2026-02-02 | $-0.50 | $-0.48 | -4.2% | $103.7M | $107.7M | -3.7% |
| 2025-11-14 | $-0.45 | $-0.50 | +10.0% | $99.0M | $97.4M | +1.7% |
| 2025-08-04 | $-0.47 | $-0.54 | +13.0% | $96.1M | $97.4M | -1.4% |
| 2025-05-05 | $-0.66 | $-0.56 | -17.9% | $92.8M | $95.4M | -2.7% |
| 2025-02-03 | $-0.53 | $-0.62 | +14.5% | $88.7M | $86.9M | +2.0% |
| 2024-11-18 | $-0.59 | $-0.71 | +17.4% | $84.7M | $82.7M | +2.4% |
| 2024-08-02 | $-0.86 | $-0.79 | -8.9% | $81.5M | $82.2M | -0.9% |
| 2024-05-02 | $-0.79 | $-0.84 | +6.0% | $75.3M | $77.4M | -2.7% |
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 376.57M | 312.97M | 245.11M | 203.56M | 132.33M | 90.10M | 54.38M | 25.43M | 10.77M | 2.27M |
| Net Income | (77.67M) | (208.73M) | (204.62M) | (217.86M) | (152.10M) | (139.93M) | (107.67M) | (71.24M) | (59.31M) | (44.09M) |
| EPS | -1.30 | -3.60 | -3.60 | -4.04 | -3.15 | -3.57 | -3.92 | -2.68 | -3.16 | -2.35 |
| Total Assets | 641.86M | 614.32M | 776.40M | 961.38M | 702.10M | 398.88M | 186.99M | 115.79M | 85.66M | 76.46M |
| Total Debt | 137.32M | 85.03M | 94.07M | 94.91M | 62.92M | 35.98M | 7.73M | 9.72M | 9.15M | 11.18M |
| Cash & Equivalents | 183.05M | 226.32M | 286.47M | 378.69M | 465.83M | 93.67M | 46.73M | 80.76M | 31.23M | 28.60M |
| Operating Cash Flow | (47.63M) | (64.09M) | (142.47M) | (124.39M) | (112.24M) | (142.25M) | (87.94M) | (66.16M) | (51.30M) | (38.59M) |
| Free Cash Flow | (75.63M) | (69.17M) | (170.25M) | (226.24M) | (139.31M) | (152.12M) | (102.69M) | (69.85M) | (57.90M) | (44.82M) |
| FCF per Share | -1.26 | -1.19 | -2.99 | -4.20 | -2.89 | -3.88 | -3.74 | -2.63 | -3.08 | -2.39 |
| Book Value | 472.96M | 472.69M | 623.43M | 789.38M | 580.82M | 336.26M | 152.08M | (201.42M) | (133.36M) | (76.61M) |
| Cash & ST Investments | 232.43M | 276.40M | 336.41M | 504.97M | 477.86M | 290.00M | 138.11M | 80.76M | 62.20M | 55.92M |
| ROC Equity | -0.16 | -0.44 | -0.33 | -0.28 | -0.26 | -0.42 | -0.71 | N/A | N/A | N/A |